• XL092,CAS#2367004-54-2

    Description: XL092 is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values in cell-based assays of 15, 1.6, 3.4, and 7.2 nM respectively. In xenograft studies, XL092 caused substantial tumor growth inhibition following 10 mg/kg daily oral dosing for 14 days. XL092 has good oral bioavailability and a significantly shorter half-life than cabozantinib.